Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol

Pharmacological Reports

Volumn 62, Issue 5, 2010, Pages 797-807

  Biała, Grazyna ^a   Budzyńska, Barbara ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Ethanol; Nicotine; Reinstatement; Rimonabant; Rodents; Sensitization

Indexed keywords

ALCOHOL; NICOTINE; RIMONABANT;

ALCOHOLISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR THERAPY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; LOCOMOTION; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PLASTICITY; RAT; REINFORCEMENT; REPEAT PROCEDURE; VALIDATION PROCESS;

EID: 79551494299     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70340-6     Document Type: Article

References (53)

1. Al-Rejaie S, Dar MS: Possible role of mouse cerebellar nitric oxide in the behavioral interaction between chronic intracerebellar nicotine and acute ethanol administration: observation of cross-tolerance. Neuroscience, 2006, 138, 575-585.
2. Biała G: Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol, 2003, 55, 327-335.
3. Biała G, Budzyńska B: Calcium-dependent mechanisms of the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Biochem Behav, 2008, 89, 116-125.
4. Biała G, Budzyńska B: Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur J Pharmacol, 2006, 537, 85-93.
5. Biała G, Wȩglińska B: Calcium channel antagonists attenuate cross-sensitization to the locomotor effects of nicotine and ethanol in mice. Pol J Pharmacol, 2004, 56, 391-397.
6. Biała G, Wȩglińska B: Calcium channel antagonists attenuate cross-sensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J Pharm Pharmacol, 2004, 56, 1021-1028.
7. Blomquist O, Soderpalm B, Engel JA: Ethanol-induced locomotor activity: involvement of central nicotinic receptors? Brain Res Bull, 1992, 29, 173-179.
8. Booker TK, Collins AC: Long-term ethanol treatment elicits changes in nicotinic receptor binding in only a few brain regions. Alcohol, 1997, 14, 131-140.
9. Budzyńska B, Kruk M, Biała G: Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Rep, 2009, 61, 304-310.
10. Calcagnetti DJ, Schechter MD: Nicotine place preference using the biased method of conditioning. Prog Neuropsychopharmacol Biol Psychiatry, 1994, 18, 925-933.
11. Carr GD, Fibiger HC, Phillips AG: Conditioned place preference as a measure of drug reward. In: The neuropharmacological basis of reward. Eds. Liebman JM, Cooper SJ, Oxford University Press, Oxford, 1989, 264-319.
12. Castañe A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O: Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology, 2002, 43, 857-867.
13. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M et al.: Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci, 2005, 21, 2243-2251.
14. Clark A, Lindgren SP, Brooks SP, Watson WP, Little HJ: Chronic infusion of nicotine can increase operant self-administration of alcohol. Neuropharmacology, 2001, 41, 108-117.
15. Cohen C, Perrault G, Griebel G, Soubrié P: Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology, 2005, 30, 145-155.
16. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P: SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol, 2002, 13, 451-463.
17. Collins AC, Wilkins LH, Slobe BS, Cao JZ, Bullock AE: Long term ethanol and nicotine treatment elicit tolerance to ethanol. Alcohol Clin Exp Res, 1996, 20, 990-999.
18. Dani JA, Ji D, Zhou FM: Synaptic plasticity and nicotine addiction. Neuron, 2001, 31, 349-352.
19. Davis TJ, de Fiebre CM: Alcohol's actions on neuronal nicotinic acetylcholine receptors. Alcohol Res Health, 2006, 29, 179-185.
20. De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer AN: Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl), 2003, 168, 164-169.
21. Diergaarde L, de Vries W, Raasø H, Schoffelmeer AN, De Vries TJ: Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A). Neuropharmacology, 2008, 55, 712-716.
22. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, Trabace et al.: Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology, 2006, 183, 394-403.
23. Funk D, Marinelli PW, Lê AD: Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors [review]. Alcohol Res Health, 2006, 29, 186-192.
24. Gonzáles S, Cascio M, Fernández-Ruiz J, Di Marzo V, Ramos J: Changes in endocannabinoid contents in the brain of rats chronically expose to nicotine, ethanol or cocaine. Brain Res, 2002, 954, 73-81.
25. Hashimoto E, Sakaguchi S, Shiga M, Ikeda N, Toki S, Saito T: Epidemiological studies of tobacco smoking and dependence in Japan. Alcohol, 2001, 24, 107-110.
26. Hoshaw BA, Lewis J: Behavioral sensitization to ethanol in rats: evidence from the Sprague-Dawley strain. Pharmacol Biochem Behav, 2001, 68, 685-690.
27. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C: Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem, 2003, 84, 698-704.
28. Koob GF: Neural mechanisms of drug reinforcement. Ann NY Acad Sci, 1992, 654, 171-191.
29. Korkosz A, Scińska A, Taracha E, Płaźnik A, Kukwa A, Kostowski W, Bieńkowski P: Nicotine-induced conditioned taste aversion in the rat: effects of ethanol. Eur J Pharmacol, 2006, 537, 99-105.
30. Larsson A, Edstrom L, Svensson L, Söderpalm B, Engel JA: Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. Alcohol Alcohol, 2005, 40, 349-358.
31. Larsson A, Engel JA: Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci Biobehav Rev, 2004, 27, 713-720.
32. Larsson A, Svensson L, Söderpalm B, Engel JA: Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol, 2002, 28, 157-167.
33. Le AD, Corrigall WA, Harding JW, Juzytsch W, Li TK: Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res, 2000, 24, 155-163.
34. Le Foll B, Goldberg SR: Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport, 2004, 15, 2139-2143.
35. Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV: Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep, 2009, 61, 217-224.
36. Maldonado R, Valverde O, Berrendero F: Involvement of the endocannabinoid system in drug addiction. Trends Neurosci, 2006, 29, 225-232.
37. Marks JL, Hill EM, Pomerleau CS, Mudd SA, Blow FC: Nicotine dependence and withdrawal in alcoholic and nonalcoholic ever-smokers. J Subst Abuse Treat, 1997, 14, 521-527.
38. Nadal R, Samson HH: Operant ethanol self-administration after nicotine treatment and withdrawal. Alcohol, 1999, 17, 139-147.
39. Nestler EJ: Is there a common molecular pathway for addiction? Nat Neurosci, 2005, 8, 1445-1449.
40. Onaivi ES: An endocannabinoid hypothesis of drug reward and drug addiction. Ann NY Acad Sci, 2008, 1139, 412-421.
41. Rezvani AH, Levin ED: Nicotine-alcohol interactions and attentional performance on an operant visual signal detection task in female rats. Pharmacol Biochem Behav, 2003, 76, 75-83.
42. Rezvani AH, Levin ED: Nicotine-alcohol interactions and cognitive function in rats. Pharmacol Biochem Behav, 2002, 72, 865-872.
43. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett, 1994, 350, 240-244.
44. Risinger FO, Roger, AO: Nicotine-induced conditioned place preference and conditioned aversion in mice. Pharmacol Biochem Behav, 1995, 51, 457-461.
45. Robinson TE, Berridge KC: The incentive sensitization theory of addiction: some current issues. Phil Trans R Soc B, 2008, 363, 3137-3146.
46. Robles N, Sabriá J: Effects of moderate chronic ethanol consumption on hippocampal nicotinic receptors and associative learning. Neurobiol Learn Mem, 2008, 89, 497-503.
47. Söderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA: Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res, 2000, 113, 85-96.
48. Spyraki C, Fibiger HC, Phillips AG: Dopaminergic substrates of amphetamine-induced place preference conditioning. Brain Res, 1982, 53, 185-193. (Pubitemid 13212230)
49. Tizabi Y, Bai L, Copeland RL Jr, Taylor RE: Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol, 2007, 42, 413-416.
50. Watson WP, Little J: Prolonged effects of chronic ethanol treatment on responses to repeated nicotine administration: interactions with environmental cues. Neuropharmacology, 1999, 38, 587-595.
51. Weiss F, Porrino LJ: Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci, 2002, 22, 3332-3337.
52. Wonnacott S: Presynaptic nicotinic ACh receptors. Trends Neurosci, 1997, 20, 92-98.
53. Zaniewska M, Przegaliński E, Filip M: Nicotine dependence - human and animal studies, current pharmacotherapies and future perspectives. Pharmacol Rep, 2009, 61, 957-965.